MarketCap
Facebook
X
Telegram
Matinas BioPharma Holdings Balance Sheet 2025-2011 | MTNB
Brief overview of Matinas BioPharma Holdings's balance sheet strength
The comparison uses five available annual reports from the 2021–2025 interval.
Assets fell from $61.3 million to $7.2 million. This may reflect either deliberate optimization or a reduction in business scale.
Liabilities expanded faster than the asset base, -73.1% versus -88.2%. Debt-service capacity deserves attention.
Equity funds 67% of assets versus 85.6% initially. This creates a conservative balance sheet structure.
Net debt moved below zero to -$3.3 million, reflecting surplus cash over debt.
The cash share moved from 34.3% to 55.5%. A higher figure generally provides more room in an adverse scenario.
The balance sheet carries negative retained earnings of -$210.8 million. The figure may result from accumulated losses or an active capital return policy.
Overall picture
Matinas BioPharma Holdings has a workable but not unconditionally strong balance sheet. Resilience depends on sustained earnings and liability control.
Annual Balance Sheet Matinas BioPharma Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.3 M | -6.51 M | -4.11 M | -6.25 M | -20.5 M | -8.68 M | -17.9 M | -12.1 M | -7.04 M | -3.96 M | -3.22 M | -2.53 M | -10.8 M | - | - |
Long Term Debt |
5 K | 12 K | 18 K | 22 K | 3 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
694 K | 761 K | 656 K | 562 K | 539 K | 391 K | 424 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
915 K | 2.38 M | 3.24 M | 3.9 M | 4.48 M | 3.67 M | 4.09 M | 962 K | 1.52 M | 1.22 M | 1.21 M | 15.3 K | - | - | - |
Total Current Liabilities |
1.46 M | 2.67 M | 2.62 M | 4.29 M | 4.35 M | 3.57 M | 3.1 M | 2.84 M | 2.22 M | 1.44 M | 1.13 M | 1.12 M | - | - | - |
Total Liabilities |
2.38 M | 5.05 M | 5.86 M | 8.18 M | 8.83 M | 7.24 M | 7.19 M | 3.8 M | 3.74 M | 2.67 M | 2.33 M | 1.13 M | 859 K | - | - |
Deferred Revenue |
- | - | - | - | - | 643 K | 100 K | - | 29.9 K | - | - | - | - | - | - |
Retained Earnings |
-211 M | -200 M | -176 M | -153 M | -132 M | -108 M | -84.4 M | -65.9 M | -51.3 M | -35.2 M | -23.2 M | -14.1 M | -3.83 M | - | - |
Total Assets |
7.21 M | 12.6 M | 25.1 M | 44.8 M | 61.3 M | 71 M | 40.2 M | 19.9 M | 14.4 M | 9.82 M | 8.41 M | 3.36 M | 11.3 M | - | - |
Cash and Cash Equivalents |
4 M | 7.28 M | 4.79 M | 6.83 M | 21 M | 12.4 M | 22.2 M | 12.4 M | 7.31 M | 4.11 M | 3.23 M | 2.59 M | 10.8 M | - | - |
Book Value |
4.83 M | 7.59 M | 19.2 M | 36.6 M | 52.5 M | 63.7 M | 33.1 M | 16.1 M | 10.7 M | 7.15 M | 6.07 M | 2.23 M | 10.5 M | - | - |
Total Shareholders Equity |
4.83 M | 7.59 M | 19.2 M | 36.6 M | 52.5 M | 63.7 M | 33.1 M | 16.1 M | 10.7 M | 7.15 M | 6.07 M | 2.23 M | 10.5 M | -117 K | - |
All numbers in USD currency
Quarterly Balance Sheet Matinas BioPharma Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
5 K | 11 K | 11 K | 11 K | 12 K | 14 K | 15 K | - | 18 K | 19 K | 20 K | 21 K | 22 K | 3.68 M | 3.84 M | 3.99 M | 2.62 K | 5.74 K | 11.5 K | 17.1 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 54.5 K | 54.5 K | 54.5 K | 54.5 K | 108 K | 108 K | 108 K | 108 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
726 K | 1.74 M | 1.96 M | 3.51 M | 2.38 M | 2.67 M | 2.87 M | - | 3.24 M | 3.41 M | 3.58 M | 3.74 M | 3.9 M | 4.03 M | 4.18 M | 4.33 M | 4.48 M | 4.63 M | 3.48 M | 3.57 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 962 K | 962 K | 962 K | 962 K | 1.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.85 M | 3.24 M | 3.75 M | 5.76 M | 5.05 M | 4.8 M | 5.26 M | - | 5.86 M | 6.64 M | 6.17 M | 5.64 M | 8.18 M | 8.93 M | 9.57 M | 8.1 M | 8.83 M | 8.73 M | 7.07 M | 5.79 M | 7.24 M | 7.24 M | 7.24 M | 7.24 M | 7.19 M | 7.19 M | 7.19 M | 7.19 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.74 M | 3.74 M | 3.74 M | 3.74 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 2.33 M | 2.33 M | 2.33 M | 2.33 M | 1.13 M | 1.13 M | 1.13 M | 1.13 M | 859 K | 859 K | 859 K | 859 K | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | 721 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.9 K | 29.9 K | 29.9 K | 29.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-213 M | -209 M | -207 M | -201 M | -200 M | -191 M | -187 M | - | -176 M | -170 M | -164 M | -158 M | -153 M | -149 M | -144 M | -138 M | -132 M | -125 M | -118 M | -112 M | -108 M | -108 M | -108 M | -108 M | -84.4 M | -84.4 M | -84.4 M | -84.4 M | -65.9 M | -65.9 M | -65.9 M | -65.9 M | -51.3 M | -51.3 M | -51.3 M | -51.3 M | -35.2 M | -35.2 M | 35.2 M | -35.2 M | -23.2 M | -23.2 M | -23.2 M | -23.2 M | -14.1 M | -14.1 M | -14.1 M | -14.1 M | -3.83 M | -3.83 M | -3.83 M | -3.83 M | - | - | - | - | - | - | - | - |
Total Assets |
5.87 M | 9.7 M | 11.4 M | 12 M | 12.6 M | 20.6 M | 24.4 M | - | 25.1 M | 29.8 M | 34 M | 38.3 M | 44.8 M | 47.5 M | 52.4 M | 55.8 M | 61.3 M | 67 M | 70 M | 72.4 M | 71 M | 71 M | 71 M | 71 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 9.82 M | 9.82 M | 9.82 M | 9.82 M | 8.41 M | 8.41 M | 8.41 M | 8.41 M | 3.36 M | 3.36 M | 3.36 M | 3.36 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
2.4 M | 5.44 M | 6.52 M | 6.92 M | 7.28 M | 10.3 M | 4.22 M | 1.07 M | 4.79 M | 6.41 M | 9.74 M | 5.74 M | 6.83 M | 11.2 M | 10.4 M | 19.3 M | 21 M | 24.9 M | 30.4 M | 23.4 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 7.31 M | 7.31 M | 7.31 M | 7.31 M | 4.1 M | 4.11 M | 4.11 M | 4.11 M | 3.23 M | 3.23 M | 3.23 M | 3.23 M | 2.59 M | 2.59 M | 2.59 M | 2.59 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 424 K | - | - | - | - | - | - | - |
Book Value |
3.02 M | 6.46 M | 7.68 M | 6.27 M | 7.59 M | 15.8 M | 19.1 M | - | 19.2 M | 23.2 M | 27.9 M | 32.6 M | 36.6 M | 38.6 M | 42.8 M | 47.7 M | 52.5 M | 58.3 M | 62.9 M | 66.6 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.15 M | 7.15 M | 7.15 M | 7.15 M | 6.07 M | 6.07 M | 6.07 M | 6.07 M | 2.23 M | 2.23 M | 2.23 M | 2.23 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
3.02 M | 6.46 M | 7.68 M | 6.27 M | 7.59 M | 15.8 M | 19.1 M | 14.6 M | 19.2 M | 23.2 M | 27.9 M | 32.6 M | 36.6 M | 38.6 M | 42.8 M | 47.7 M | 52.5 M | 58.3 M | 62.9 M | 66.6 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.15 M | 7.15 M | 7.15 M | 7.15 M | 6.07 M | 6.07 M | 6.07 M | 6.07 M | 2.23 M | 2.23 M | 2.23 M | 2.23 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | -117 K | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Matinas BioPharma Holdings, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
